PL4171572T3 - Formulacje tabletek dyspergowalnych zawierające dolutegrawir - Google Patents

Formulacje tabletek dyspergowalnych zawierające dolutegrawir

Info

Publication number
PL4171572T3
PL4171572T3 PL21737779.5T PL21737779T PL4171572T3 PL 4171572 T3 PL4171572 T3 PL 4171572T3 PL 21737779 T PL21737779 T PL 21737779T PL 4171572 T3 PL4171572 T3 PL 4171572T3
Authority
PL
Poland
Prior art keywords
dolutegravir
formulations containing
tablet formulations
dispersable tablet
dispersable
Prior art date
Application number
PL21737779.5T
Other languages
English (en)
Inventor
Ian Paul Conn
Mark Robert Davies
Joanne Heafield
Michael Holton
Neil Mortimer
Original Assignee
Viiv Healthcare Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Company filed Critical Viiv Healthcare Company
Publication of PL4171572T3 publication Critical patent/PL4171572T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21737779.5T 2020-06-26 2021-06-23 Formulacje tabletek dyspergowalnych zawierające dolutegrawir PL4171572T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2009684.8A GB202009684D0 (en) 2020-06-26 2020-06-26 Formulations
PCT/IB2021/055533 WO2021260567A1 (en) 2020-06-25 2021-06-23 Dispersible tablet formulations comprising dolutegravir

Publications (1)

Publication Number Publication Date
PL4171572T3 true PL4171572T3 (pl) 2025-08-25

Family

ID=71949817

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21737779.5T PL4171572T3 (pl) 2020-06-26 2021-06-23 Formulacje tabletek dyspergowalnych zawierające dolutegrawir

Country Status (19)

Country Link
US (1) US20230285307A1 (pl)
EP (1) EP4171572B1 (pl)
JP (1) JP2023531086A (pl)
KR (1) KR20230028288A (pl)
CN (1) CN115697344B (pl)
AR (1) AR122718A1 (pl)
AU (1) AU2021296506B2 (pl)
BR (1) BR112022026243A2 (pl)
CA (1) CA3180544A1 (pl)
CL (1) CL2022003743A1 (pl)
ES (1) ES3033621T3 (pl)
FI (1) FI4171572T3 (pl)
GB (1) GB202009684D0 (pl)
IL (1) IL298353A (pl)
MX (1) MX2022015438A (pl)
PL (1) PL4171572T3 (pl)
PT (1) PT4171572T (pl)
TW (1) TW202216154A (pl)
WO (1) WO2021260567A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114191404B (zh) * 2022-01-10 2023-06-27 安徽贝克生物制药有限公司 一种多替拉韦片剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015006558A2 (pt) * 2012-10-23 2017-07-04 Cipla Ltd composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar doenças causadas por retrovírus
EP2956123A1 (en) * 2013-02-18 2015-12-23 ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014184553A1 (en) * 2013-05-15 2014-11-20 Cipla Limited Pharmaceutical antiretroviral compositions
IN2014MU00916A (pl) * 2014-03-20 2015-09-25 Cipla Ltd
CA2975884A1 (en) * 2015-02-06 2016-08-11 Mylan Laboratories Limited Processes for the preparation of dolutegravir
HK1254620A1 (zh) * 2015-10-14 2019-07-26 结核病药物开发全球联盟公司 联合抗菌组合物以及短疗程抗菌方案

Also Published As

Publication number Publication date
IL298353A (en) 2023-01-01
PT4171572T (pt) 2025-06-16
CL2022003743A1 (es) 2023-06-30
JP2023531086A (ja) 2023-07-20
AU2021296506B2 (en) 2024-08-22
GB202009684D0 (en) 2020-08-12
AR122718A1 (es) 2022-09-28
EP4171572B1 (en) 2025-05-21
CN115697344B (zh) 2025-04-04
CA3180544A1 (en) 2021-12-30
AU2021296506A1 (en) 2023-01-05
ES3033621T3 (en) 2025-08-06
FI4171572T3 (fi) 2025-08-08
EP4171572A1 (en) 2023-05-03
KR20230028288A (ko) 2023-02-28
TW202216154A (zh) 2022-05-01
US20230285307A1 (en) 2023-09-14
BR112022026243A2 (pt) 2023-01-17
WO2021260567A1 (en) 2021-12-30
CN115697344A (zh) 2023-02-03
MX2022015438A (es) 2023-03-22

Similar Documents

Publication Publication Date Title
EP4045480A4 (en) PHARMACEUTICAL FORMULATIONS
DK3638251T3 (da) Bisphosphocin gel formuleringer og brug deraf
IL285674A (en) Pharmaceutical formulations
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
DK4233850T3 (da) Kapselformuleringer
DK3651736T3 (da) Langtidsvirkende formuleringer
EP3976001A4 (en) APREMILAST TABLET FORMULATIONS
IL269305A (en) Cannabinoid formulations and dosage
EP4013441A4 (en) LARAZOTIDE FORMULATIONS
DK3911298T3 (da) Formuleringer
GB202005282D0 (en) Pharmaceutical Formulations
EP4352194C0 (en) COMPOSITION OF TABLET
EP4447714C0 (en) NICOTINE TABLET
PL4171572T3 (pl) Formulacje tabletek dyspergowalnych zawierające dolutegrawir
EP3746080A4 (en) PHARMACEUTICAL FORMULATIONS
EP3784672A4 (en) Tablet formulations comprising metformin and sitagliptin
EP4099999C0 (en) DOCETAXEL FORMULATIONS
EP3976000C0 (en) VAGINAL TABLET FORMULATION
DK3790529T5 (da) Formuleringer indeholdende aktive oxygenforbindelser og anordninger til anvendelse deraf
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
IL310652A (en) Formulations of radiprodil
EP3810137A4 (en) NITROIMIDAZOLE FORMULATIONS
EP4284362A4 (en) Formulations
EP3651800C0 (en) HYDROCOMPRESSED PHARMACEUTICAL FORMULATIONS
EP4188088A4 (en) Formulations